Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirati Therapeutics (DE:26M)
FRANKFURT:26M
Mirati Therapeutics (26M) Stock Price & Analysis
0 Followers
26M Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€25.13 - €59.46
Previous Close€53.3
Volume0.00
Average Volume (3M)103.00
Market Cap
€3.79B
Enterprise Value€2.93B
Total Cash (Recent Filing)$976.43M
Total Debt (Recent Filing)$42.20M
Price to Earnings (P/E)N/A
Beta-0.37
Next Earnings
Feb 27, 2024EPS Estimate
-€2.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,147,706
10 Day Avg. Volume0
30 Day Avg. Volume103
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)4.35
Price to Sales (P/S)295.46
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue77.25
Enterprise Value/Gross Profit235.21
Enterprise Value/Ebitda-4.07
Forecast
1Y Price Target
€53.94Price Target Upside1.19% Upside
Rating ConsensusHold
Number of Analyst Covering5
Mirati Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.49% Other Institutional Investors
99.51% Public Companies and
Individual Investors
26M FAQ
What was Mirati Therapeutics’s price range in the past 12 months?
Mirati Therapeutics lowest stock price was €25.13 and its highest was €59.46 in the past 12 months.
What is Mirati Therapeutics’s market cap?
Currently, no data Available
When is Mirati Therapeutics’s upcoming earnings report date?
Mirati Therapeutics’s upcoming earnings report date is Feb 27, 2024 which is 60 days ago.
How were Mirati Therapeutics’s earnings last quarter?
Mirati Therapeutics released its earnings results on Nov 06, 2023. The company reported -€2.293 earnings per share for the quarter, beating the consensus estimate of -€2.61 by €0.317.
Is Mirati Therapeutics overvalued?
According to Wall Street analysts Mirati Therapeutics’s price is currently Undervalued.
Does Mirati Therapeutics pay dividends?
Mirati Therapeutics does not currently pay dividends.
What is Mirati Therapeutics’s EPS estimate?
Mirati Therapeutics’s EPS estimate is -€2.41.
How many shares outstanding does Mirati Therapeutics have?
Currently, no data Available
What happened to Mirati Therapeutics’s price movement after its last earnings report?
Mirati Therapeutics reported an EPS of -€2.293 in its last earnings report, beating expectations of -€2.61. Following the earnings report the stock price went down -0.693%.
Which hedge fund is a major shareholder of Mirati Therapeutics?
Among the largest hedge funds holding Mirati Therapeutics’s share is Baker Bros Advisors LP. It holds Mirati Therapeutics’s shares valued at 61M.
---
Mirati Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€53.94 (1.19% Upside)
€53.94 (1.19% Upside)
Blogger Sentiment
Bullish
DE:26M Sentiment 88%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $877.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-69.95%
Trailing 12-Months
Asset Growth
-13.30%
Trailing 12-Months
Company Description
Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
---
26M Earnings Call
Q2 2023
0:00 / 0:00
---
26M Stock 12 Months Forecast
Average Price Target
€53.94
▲(1.19% Upside)
Technical Analysis
Best Analysts Covering 26M
1 Year
1 Year Success Rate
12/17 ratings generated profit
1 Year Average Return
+40.28%
reiterated a buy rating 7 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +40.28% per trade.
---